FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2962783208> ?p ?o ?g. }

• W2962783208 endingPage "439" @default.
• W2962783208 startingPage "429" @default.
• W2962783208 abstract "Abstract Background Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. The object of this study was to refine a population PK model that accurately predicts individual IFX exposure during maintenance therapy using longitudinal real-practice data. Methods We exported data from the electronic health records of pediatric patients with IBD treated with originator IFX at a single center between January 2011 and March 2017. Subjects were divided into discovery and validation cohorts. A population PK model was built and then validated. Results We identified 228 pediatric patients with IBD who received IFX and had at least 1 drug concentration measured, including 135 and 93 patients in the discovery and validation cohorts, respectively. Weight, albumin, antibodies to IFX (ATI) detected by a drug-tolerant assay, and erythrocyte sedimentation rate (ESR) were identified as covariates significantly associated with IFX clearance and incorporated into the model. The model exhibited high accuracy for predicting target IFX trough concentrations with an area under the receiver operating characteristic curve (AUROC) of 0.86 (95% confidence interval [CI], 0.81–0.91) for population-based predictions without prior drug-level input. Accuracy increased further for individual-based predictions when prior drug levels were known, with an AUROC of 0.93 (95% CI, 0.90–0.97). Conclusions A population PK model utilizing weight, albumin, ordinal drug-tolerant ATI, and ESR accurately predicts IFX trough concentrations during maintenance therapy in real-practice pediatric patients with IBD. This model, which incorporates dynamic clinical information, could be used for individualized dosing decisions to increase response durability." @default.
• W2962783208 created "2019-07-30" @default.
• W2962783208 creator A5013881333 @default.
• W2962783208 creator A5016058238 @default.
• W2962783208 creator A5040060343 @default.
• W2962783208 creator A5051483318 @default.
• W2962783208 creator A5077172026 @default.
• W2962783208 creator A5078149270 @default.
• W2962783208 creator A5080488710 @default.
• W2962783208 creator A5090500677 @default.
• W2962783208 date "2019-07-09" @default.
• W2962783208 modified "2023-10-13" @default.
• W2962783208 title "Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease" @default.
• W2962783208 cites W1973651333 @default.
• W2962783208 cites W2006783956 @default.
• W2962783208 cites W2007196095 @default.
• W2962783208 cites W2027142766 @default.
• W2962783208 cites W2043780895 @default.
• W2962783208 cites W2064877889 @default.
• W2962783208 cites W2066789917 @default.
• W2962783208 cites W2066996342 @default.
• W2962783208 cites W2070379183 @default.
• W2962783208 cites W2071871684 @default.
• W2962783208 cites W2076523377 @default.
• W2962783208 cites W2088135039 @default.
• W2962783208 cites W2095161324 @default.
• W2962783208 cites W2102245241 @default.
• W2962783208 cites W2103755206 @default.
• W2962783208 cites W2114266978 @default.
• W2962783208 cites W2124042932 @default.
• W2962783208 cites W2126807394 @default.
• W2962783208 cites W2136589391 @default.
• W2962783208 cites W2146963207 @default.
• W2962783208 cites W2157298598 @default.
• W2962783208 cites W2215127226 @default.
• W2962783208 cites W2244428638 @default.
• W2962783208 cites W2321351874 @default.
• W2962783208 cites W2345626471 @default.
• W2962783208 cites W2467713688 @default.
• W2962783208 cites W2519393083 @default.
• W2962783208 cites W2530995556 @default.
• W2962783208 cites W2586142976 @default.
• W2962783208 cites W2605997778 @default.
• W2962783208 cites W2608036493 @default.
• W2962783208 cites W2611555333 @default.
• W2962783208 cites W2744879509 @default.
• W2962783208 cites W2782782475 @default.
• W2962783208 cites W2790432738 @default.
• W2962783208 cites W4238048406 @default.
• W2962783208 cites W4321429438 @default.
• W2962783208 doi "https://doi.org/10.1093/ibd/izz143" @default.
• W2962783208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7171445" @default.
• W2962783208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31287855" @default.
• W2962783208 hasPublicationYear "2019" @default.
• W2962783208 type Work @default.
• W2962783208 sameAs 2962783208 @default.
• W2962783208 citedByCount "29" @default.
• W2962783208 countsByYear W29627832082020 @default.
• W2962783208 countsByYear W29627832082021 @default.
• W2962783208 countsByYear W29627832082022 @default.
• W2962783208 countsByYear W29627832082023 @default.
• W2962783208 crossrefType "journal-article" @default.
• W2962783208 hasAuthorship W2962783208A5013881333 @default.
• W2962783208 hasAuthorship W2962783208A5016058238 @default.
• W2962783208 hasAuthorship W2962783208A5040060343 @default.
• W2962783208 hasAuthorship W2962783208A5051483318 @default.
• W2962783208 hasAuthorship W2962783208A5077172026 @default.
• W2962783208 hasAuthorship W2962783208A5078149270 @default.
• W2962783208 hasAuthorship W2962783208A5080488710 @default.
• W2962783208 hasAuthorship W2962783208A5090500677 @default.
• W2962783208 hasBestOaLocation W29627832082 @default.
• W2962783208 hasConcept C112705442 @default.
• W2962783208 hasConcept C126322002 @default.
• W2962783208 hasConcept C2777138892 @default.
• W2962783208 hasConcept C2777288759 @default.
• W2962783208 hasConcept C2778143017 @default.
• W2962783208 hasConcept C2778260677 @default.
• W2962783208 hasConcept C2779134260 @default.
• W2962783208 hasConcept C2780272996 @default.
• W2962783208 hasConcept C2908647359 @default.
• W2962783208 hasConcept C2909675724 @default.
• W2962783208 hasConcept C2910800852 @default.
• W2962783208 hasConcept C2911091166 @default.
• W2962783208 hasConcept C31785415 @default.
• W2962783208 hasConcept C44249647 @default.
• W2962783208 hasConcept C58471807 @default.
• W2962783208 hasConcept C71924100 @default.
• W2962783208 hasConcept C76318530 @default.
• W2962783208 hasConcept C90924648 @default.
• W2962783208 hasConcept C99454951 @default.
• W2962783208 hasConceptScore W2962783208C112705442 @default.
• W2962783208 hasConceptScore W2962783208C126322002 @default.
• W2962783208 hasConceptScore W2962783208C2777138892 @default.
• W2962783208 hasConceptScore W2962783208C2777288759 @default.
• W2962783208 hasConceptScore W2962783208C2778143017 @default.
• W2962783208 hasConceptScore W2962783208C2778260677 @default.
• W2962783208 hasConceptScore W2962783208C2779134260 @default.
• W2962783208 hasConceptScore W2962783208C2780272996 @default.

• next